MYBL2 and hepatocellular carcinoma: B-Myb has been shown to be overexpressed in a broad range of human cancers, such as breast cancer [18], hepatocellular carcinoma [10], lung cancer [19], colon cancer [20], neuroblastoma [21], and T-cell lymphomas [22].